MARKET

MDGL

MDGL

Madrigal Pharmac
NASDAQ
231.37
-5.22
-2.21%
Closed 19:43 04/15 EDT
OPEN
237.00
PREV CLOSE
236.59
HIGH
242.99
LOW
228.82
VOLUME
323.00K
TURNOVER
0
52 WEEK HIGH
322.67
52 WEEK LOW
119.76
MARKET CAP
4.85B
P/E (TTM)
-11.5724
1D
5D
1M
3M
1Y
5Y
UPDATE 2-Organovo's drug significantly reduces liver fat in NASH study
Organovo's drug significantly reduces liver fat in NASH study. Shares of the small biotech firm surged 44% to $1.45 in early trading on Monday. Company's drug reduced liver fat by as much as 22.8% in a mid-stage study of some patients with NASH. The oral drug, FXR314, helped improve liver function.
Reuters · 1d ago
Weekly Report: what happened at MDGL last week (0408-0412)?
Weekly Report · 1d ago
2 Under-the-Radar Growth Stocks to Consider
Madrigal Pharmaceuticals recently earned approval for its first medicine on the market for a severe liver disease. Axsome Therapeutics has exciting possibilities in its pipeline. Madrigal has underperformed the market over the past year, but there could be plenty of upside for investors.
The Motley Fool · 6d ago
Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX) and Madrigal Pharmaceuticals (MDGL)
TipRanks · 6d ago
Madrigal announces US launch of NASH/MASH drug Rezdiffra
Healthcare Madrigal announces US launch of NASH/MASH drug Rezdiffra. The drug is now available in the US through a specialty pharmacy network. Other companies working on therapies for NASH and MASH include Eli Lilly and Novo Nordisk. MadrigAL is the first to receive FDA approval for the treatment of the disease.
Seeking Alpha · 04/09 14:03
MADRIGAL PHARMACEUTICALS ANNOUNCES U.S. AVAILABILITY OF REZDIFFRA™ (RESMETIROM) FOR THE TREATMENT OF PATIENTS WITH NONCIRRHOTIC NASH WITH MODERATE TO ADVANCED LIVER FIBROSIS
Reuters · 04/09 12:00
Weekly Report: what happened at MDGL last week (0401-0405)?
Weekly Report · 04/08 09:26
Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics
NASDAQ · 04/05 11:15
More
About MDGL
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.

Webull offers Madrigal Pharmaceuticals Inc stock information, including NASDAQ: MDGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDGL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MDGL stock methods without spending real money on the virtual paper trading platform.